Top Markets
#1 Black Phoenix Black Phoenix +167.57%
#2 Islamic Coin Islamic Coin +158.27%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +29.49%
#5 Test Test +21.48%
#6 Cryptopia Cryptopia +20.92%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.26%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +17.98%
#9 stake.link stake.link +9.38%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.26%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Classifica tra le azioni #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Prezzo delle azioni
$0.0009
Ultima sincronizzazione: 2025-05-27
Capitalizzazione di mercato
$1.15K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Arch Therapeutics, Inc. (ARTH)

Categoria

Healthcare
Utile per Arch Therapeutics, Inc. (ARTH)
Utile nel Jun 2024 TTM: $-12.26M
Secondo gli ultimi rapporti finanziari di Arch Therapeutics, Inc., gli utili attuali della società sono $-12.26M. Nel 2022, la società ha registrato un utile di $-5.28M, un aumento rispetto a agli utili del 2021, che erano di $-6.24M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Arch Therapeutics, Inc. dal 2011 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-12.26M 75.61%
2023 $-6.98M 32.35%
2022 $-5.28M -15.46%
2021 $-6.24M 33.02%
2020 $-4.69M 3.16%
2019 $-4.55M -5.53%
2018 $-4.81M -38.19%
2017 $-7.79M 29.98%
2016 $-5.99M 103.30%
2015 $-2.95M -63.80%
2014 $-8.14M 339.25%
2013 $-1.85M 4,963.48%
2012 $-36.61K 626.84%
2011 $-5.04K 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -43,115.92%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -16,007.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,611.12%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR